Advisory Board

John Eadie

MPA
Public Health and PDMP Project Coordinator
Drug Threat Analysis Group (DTAG)

John L. Eadie is the Public Health and Prescription Drug Monitoring Programs (PDMP) Project Coordinator for the Drug Threats Analysis Group (DTAG), a national program of the High Intensity Drug Trafficking Areas (HIDTA) Program. His 54 years in public health include 39 years enhancing PDMPs.

As Director of the Division of Public Health Protection in the NY State Department of Health from 1985 to 1995, he directed the State’s pharmaceutical diversion program, including the PDMP. He co-founded the Alliance of States with Prescription Monitoring Programs (ASPMP) and the National Association of State Controlled Substances Authorities (NASCSA). After leaving NY State in 2001, he served as a PDMP consultant. From 2010 to 2015, he was the founding Director of the PDMP Center of Excellence (COE) at Brandeis University.

In 2015, he transferred to the HIDTA Program to help develop a National Emerging Threats Initiative, an early warning system to identify major changes in drug abuse.

He has published multiple articles, made numerous presentations, and served in many arenas as an expert.

He is the recipient of the 2019 Congressman Hal Rogers Beacon of Hope Award at the April 2019 Rx Drug Abuse & Heroin Summit in Atlanta, GA.

2027 Sessions

Major Changes in Prescribing of Opioids, Stimulants, and Other Drugs: 2010 through 2025

Session Description: Prescribing patterns and overdose death trends related to prescription controlled substances are changing each year. As learned through the opioid epidemic, such changes can have significant impacts on national and state substance use disorders, overdoses, and deaths. While prescription opioids, including fentanyl, have seen a decline in both prescribing and overdose deaths for more than a decade, the rate of decrease has slowed during the past five years. While illicit fentanyl recently surged and has significantly contributed to the national rise in drug overdose deaths, the rate of prescribing licit fentanyl has decreased even more rapidly than other prescription opioids. These decreases are consistent with public policy initiatives taken in the 2010s decades. At the same time, buprenorphine prescribing has more than tripled since 2010 in its enhanced role as Medications for Opioid Use Disorder (MOUD). The use of prescription benzodiazepines and overdose deaths involving these drugs have followed the patterns of prescription opioid prescribing and deaths.On the other hand, areas with limited public policy attention are seeing increases in prescribing and overdose deaths, particularly involving stimulants and ketamine.

Presenter

Wednesday, March 31 4:30–5:45 PM
1.25 Credits
Illicit Drugs
Advisory Board

John Eadie

MPA
Public Health and PDMP Project Coordinator
Drug Threat Analysis Group (DTAG)

John L. Eadie is the Public Health and Prescription Drug Monitoring Programs (PDMP) Project Coordinator for the Drug Threats Analysis Group (DTAG), a national program of the High Intensity Drug Trafficking Areas (HIDTA) Program. His 54 years in public health include 39 years enhancing PDMPs.

As Director of the Division of Public Health Protection in the NY State Department of Health from 1985 to 1995, he directed the State’s pharmaceutical diversion program, including the PDMP. He co-founded the Alliance of States with Prescription Monitoring Programs (ASPMP) and the National Association of State Controlled Substances Authorities (NASCSA). After leaving NY State in 2001, he served as a PDMP consultant. From 2010 to 2015, he was the founding Director of the PDMP Center of Excellence (COE) at Brandeis University.

In 2015, he transferred to the HIDTA Program to help develop a National Emerging Threats Initiative, an early warning system to identify major changes in drug abuse.

He has published multiple articles, made numerous presentations, and served in many arenas as an expert.

He is the recipient of the 2019 Congressman Hal Rogers Beacon of Hope Award at the April 2019 Rx Drug Abuse & Heroin Summit in Atlanta, GA.

Back to top